Effects of *Cymbidium* Root Ethanol Extract on Atopic Dermatitis

Wan-Joong Kim, Hae-Sim Cha, Myung-Hun Lee, Sun-Young Kim, Seo Ho Kim, and Tack-Joong Kim

Division of Biological Science and Technology, Yonsei-Fraunhofer Medical Device Laboratory, College of Science and Technology, Yonsei University, Wonju 220-710, Republic of Korea

Correspondence should be addressed to Tack-Joong Kim; ktj@yonsei.ac.kr

Received 24 November 2015; Revised 7 January 2016; Accepted 14 January 2016

Academic Editor: Salvatore Chirumbolo

Copyright © 2016 Wan-Joong Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Cymbidium* has known antibacterial and antiedema activity and has been used as an ingredient in cosmetics and fragrances. The effects of *Cymbidium* ethanol extract (CYM) on allergic response and the underlying mechanisms of action have not been reported. Therefore, the purpose of this study was to determine the effect of CYM on allergic responses. Topical application of CYM was effective against immunoglobulin E (IgE)/dinitrophenyl-conjugated bovine serum albumin- (DNP-BSA-) induced degranulation of RBL-2H3 cells and anaphylaxis in ICR mice. An allergic dermatitis-like mouse model was used to evaluate the therapeutic potential of CYM in vivo.

Continuous application of 2,4-dinitrochlorobenzene (DNCB) not only induced dermatitis in ICR mice but also aggravated the skin lesioning. However, the application of CYM decreased skin lesion severity, scratching behavior, and IgE levels. In addition, CYM downregulated the expression of the proinflammatory cytokines interleukin- (IL-) 4, IL-13, and tumor necrosis factor- (TNF-) α. Studies of signal transduction pathways showed that CYM suppressed the phosphorylation of spleen tyrosine kinase (Syk), an upstream molecule. It also inhibited the phosphorylation of Akt, phospholipase C- (PLC-) γ, and mitogen-activated protein kinase kinase kinase (MEKK). These results indicate that CYM may be effective in preventing and reducing allergic response and may have therapeutic potential as an antiallergic agent in disorders such as atopic dermatitis.

1. Introduction

An allergic response is a hypersensitive immune reaction to a diverse and complex combination of environmental and genetic factors [1–3]. It occurs in various diseases such as atopic dermatitis (AD), anaphylactic shock, asthma, and conjunctivitis [4, 5]. AD is a chronic inflammatory skin disease affecting approximately 10 million people, who are also prone to experiencing relapses. AD is accompanied by pruritus, dry skin, eczema, and keratinization [6]. It is also induced by complicated conditions and mechanisms that are closely related to increased T helper 2 lymphocytes and basophils [7, 8] while activated mast cells, increased immunoglobulin E (IgE), and production of proinflammatory cytokines are found in the skin lesions [8, 9]. Mast cells play a key role in the allergic response in conditions such as AD, food allergy, allergic rhinitis, and other similar diseases by activating a tetrameric form of the Fc epsilon receptor 1 (FceRI) [9, 10]. FceRI is also expressed in basophils and antigen-presenting dendritic cells and consists of α, β, and γ chains. The α chains directly bind the IgE heavy chains while β and γ chains are involved in signal transduction [11, 12]. The IgE produced and secreted by plasma B cells has a high affinity for IgE-specific FceRI on mast cells [13–15]. When exposed to a second IgE-specific allergen, signaling pathways in mast cells are initiated by IgE allergen cross-linking. Tyrosine kinases are phosphorylated and activated by cross-linking of FceRI by β- and γ-receptor tyrosine-based activation motifs [16]. Phosphorylation of Lyn and spleen tyrosine kinase (Syk) activates various downstream signaling molecules such as protein kinase B (Akt), phospholipase C- (PLC-) γ, and mitogen-activated protein kinase kinase kinase (MEKK) as well as PLC-γ-mediated cleavage of phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2)
to diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) [1, 17]. IP3 increases calcium ion influx into the cytosol through calcium channels [18, 19]. Degranulation of mast cells is induced by increased calcium ions in the cytosol and activation of PKC.

Following mast cell degranulation, various factors are released such as histamine, leukotrienes, prostaglandins, and other mediators that induce smooth muscle contraction, deposition of collagen and other tissues, and vasodilation [20, 21]. In addition, the activation of MEKK promotes various downstream signal transduction pathways. Mitogen-activated protein kinases (MAPKs) are downstream and regulate the production of cytokines such as interleukin- (IL-) 4, IL-13, and tumor necrosis factor- (TNF-) α. These cytokines exert proinflammatory actions associated with the allergic response [22, 23].

Cymbidium belongs to the orchid family, which is distributed throughout Southeast Asia, China, Japan, and Northern Australia. Various research studies have demonstrated that phenanthrene and phenylpropanoid extracted from the roots of Cymbidium exert antibacterial effects against hay bacillus, pneumobacillus, and Trichophyton rubrum [24]. Cymbidium has shown anti-inflammatory effects in a mouse model of carrageenan-induced edema [25]. Linalool and 4-methyl-phenol, which are isolated from the root extracts of Cymbidium, also have antioxidant potential [26]. Aromatic glucosides extracted from the roots of Cymbidium by chromatography, are used as ingredients in cosmetics and fragrances [27]. Therefore, we investigated the effects of the Cymbidium ethanol extract (CYM) on allergic responses in vitro and in vivo.

2. Material and Methods

2.1. Preparation of CYM. C. eburneo-kanran was cultivated according to the agricultural practices and methods of the Korea Rural Development Administration and harvested in Eumseong (GPS: E128°62’ N 36°56’). For extract preparation, 400 g of dried C. eburneo-kanran root was extracted thrice with 2 L of ethanol for 1 day. The resulting extracts were filtered through Whatman No. 1 paper, combined, and concentrated using a rotary evaporator (EYELA N-1000, Tokyo, Japan) at 40°C. The acquired dried extracts were subsequently lyophilized and processed into powder.

2.2. Cell Culture. RBL-2H3 is a rat cell line and was acquired from the American Type Culture Collection (ATCC, Rockville, MD, USA). The cells were cultured in Eagle’s Minimal Essential Medium (MEM, WelGENE, Inc., Daeug, Korea) supplemented with 100 units/mL penicillin-streptomycin (Sigma-Aldrich, St. Louis, MO, USA) and 10% (v/v) fetal bovine serum (FBS, Gibco, Rockville, MD, USA) at 37°C in a humidified 5% CO₂ atmosphere. Trypsin-ethylenediaminetetraacetic acid (EDTA) solution (Sigma-Aldrich) was used to detach the cells, which were washed with phosphate-buffered saline (PBS, Gibco).

2.3. Animals. Seven-week-old male ICR mice were obtained from Orient Bio (Gangneung, Korea) and housed in cages maintained in an environment with the temperature at 20–22°C and humidity of 40–50%. All the ICR mice were given access to standard laboratory chow and water ad libitum. The Institutional Animal Care and Use Committee (IACUC, YWC-141128-1) at Yonsei University (Wonju, Korea) approved the protocol for this study.

2.4. β-Hexosaminidase Release Assay. RBL-2H3 cells (1 × 10⁵ cells/mL) were seeded into 24-well culture plates and incubated overnight in MEM containing 10% (v/v) FBS at 37°C. To sensitize RBL-2H3 cells, they were incubated with antidinitrophenyl (anti-DNP) IgE at 400 ng/mL. After 12 h, the sensitized RBL-2H3 cells were washed with Siraganian buffer (pH 7.2), containing 25 mM piperazine-N,N’-bis(2-ethanesulfonic acid) (PIPES), 4 mM potassium chloride (KCl), 0.4 mM magnesium chloride (MgCl₂), 110 mM sodium chloride (NaCl), 0.1% BSA, 5.6 mM glucose, 1 mM calcium chloride (CaCl₂), and 40 mM hydrochloric acid (HCl), and then were treated with CYM (0, 25, 50, 100, or 200 µg/mL) in Siraganian buffer at 37°C for 30 min. To activate RBL-2H3 cells, diotinophenyl-conjugated-(DNP-) BSA, 50 ng/mL was added at 37°C for 15 min. Cell supernatants (30 µL) were transferred to a 96-well culture plate and mixed with 1 mM p-nitrophenyl-N-acetyl-β-D-glucosaminide (p-NAG, MP Biomedicals, OH, USA) in 0.1 M citrate buffer for 1 h. To terminate the reaction, 0.1 M carbonate buffer was added, and the absorbance of the reaction solution was measured at 405 nm using a microplate reader.

2.5. Western Blotting. RBL-2H3 cells (1 × 10⁵ cells/mL) were seeded into 24-well plates and incubated in MEM containing 10% (v/v) FBS at 37°C for 12 h. Anti-DNP IgE (400 ng/mL) was added to the medium and incubated for 12 h. Then, the medium was replaced with serum-free MEM containing CYM (0 or 200 µg/mL), followed by the addition of DNP-BSA. RBL-2H3 cells were washed twice with cold PBS and lysed, and protein was extracted using the PRO-PREP protein extraction kit (iNTRON Biotechnology, Inc., Seongnam, Korea) with a protease inhibitor containing 1 mM sodium vanadate (Na₃VO₄) and 10 mM sodium fluoride (NaF). A Bradford assay kit (BioRad, CA, USA) was used for the quantitative analysis of protein according to the manufacturer’s instructions. The protein lysates were separated using 12.5% by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene fluoride membrane (PVDF, Bio-Rad) using a Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad) for 40 min.

The PVDF membrane was blocked for 1 h with 5% skim milk in Tris-buffered saline containing 0.1% Tween-20 (TBS-T). The blocked membrane was incubated with primary antibody overnight at 4°C (1: 2000). The primary antibodies used were anti-phospho-Syk, anti-Syk, anti-phospho-PLC-γ, anti-PLC-γ, anti-phospho-Akt, anti-Akt, anti-phospho-extracellular signal-regulated kinase (Erk) 1/2, anti-Erk 1/2, anti-phospho-c-Jun N-terminal kinase (JNK), anti-JNK, anti-phospho-p38, and anti-p38, which were purchased.
Evidence-Based Complementary and Alternative Medicine

Figure 1: Effect of *Cymbidium* ethanol extract (CYM) on immunoglobulin E/dinitrophenyl-conjugated bovine serum albumin- (IgE/DNP-BSA-) induced passive cutaneous anaphylaxis. Anti-DNP IgE antibody was injected intradermally into each right ear of 7-week-old ICR mice. CYM or diphenhydramine (DPH) was administered orally to mice. After 1h, we injected 200 μg of DNP-BSA. (a) Representative images of ears. (b) Excised ears were reacted overnight with 500 μL of formamide and amount of dye taken up was determined by measuring absorbance at 620 nm using a microplate reader. Data are mean ± standard deviation (SD, n = 5); **P<0.0001 versus IgE/DNP-BSA treatment group.

2.6. Passive Cutaneous Anaphylaxis. The anti-DNP IgE antibody was injected intradermally into each right ear of 7-week-old ICR mice. After 1 day, CYM or diphenhydramine (DPH) was orally administered to the mice and, 1h later, 200 μg of DNP-BSA in 200 μL PBS containing 3% Evans Blue was injected into the tail vein. After 30 min, the mice were euthanized and their ears were excised and then incubated overnight with 500 μL of formamide at 60°C. The amount of dye taken up was determined by measuring the absorbance at 620 nm using a microplate reader.

2.7. AD-Like Mouse Model. These experiments were performed according to the method of Park et al. [28] with slight modifications. Briefly, male ICR mice were divided into three groups of six animals each, the nontreatment, 2,4-dinitrochlorobenzene (DNCB) treatment, and DNCB and CYM treatment groups. AD was induced by shaving the dorsal skin of the mice and applying a 1% DNCB solution (3:1 mixture of acetone and olive oil) for 4 days. After sensitization, mice were treated with 200 μL of 0.5% DNCB solution, and then the lesions on the dorsal skin were topically treated with 200 μL of CYM (10 mg/mL) every 2 days for a total of six times. Subsequently, the AD-like mice were euthanized. We also evaluated the progression of the severity of the dorsal skin dermatitis of the AD-like ICR mice during treatment with 0.5% DNCB or 0.5% DNCB and CYM. Five conditions were evaluated, erythema, pruritus/dry skin, erosion, lichenification, and edema/excoriation. These conditions were then scored as follows based on severity: none = 0, mild = 1, moderate = 2, and severe = 3, and the sum of the individual scores was considered the dermatitis score. To ensure the credibility of the severity test, a researcher who was not associated with the experiment and was blinded to the treatments, determined the score. In addition, to observe scratching behavior, a behavioral characteristic of AD-like mice, we video-recorded and analyzed their behavior for 60 min during treatment with 0.5% DNCB or 0.5% DNCB and CYM. The number of scratches was counted in the video recordings by a similarly blinded researcher who was
Figure 2: Effect of Cymbidium ethanol extract (CYM) on 2,4-dinitrochlorobenzene- (DNCB-) induced atopic dermatitis- (AD-) like model. Male ICR mice were divided into three groups (non-, DNCB, and DNCB and CYM treatment, n = 6). AD was induced by shaving dorsal skin of mice and applying a 1% DNCB solution for 4 days. After sensitization, mice were treated with 0.5% DNCB solution with or without CYM (10 mg/mL) every 2 days for a total of 6 times. Subsequently, AD-like mice were euthanized. (a) Image of mouse dorsal skin after euthanasia. (b) AD-like mouse model dorsal skin lesion conditions were evaluated to determine severity of dermatitis. Five symptomatic conditions were evaluated, erythema, pruritus/dry skin, erosion, lichenification, and edema/excoriation, and scored based on severity as follows: none = 0, mild = 1, moderate = 2, and severe = 3. Sum of individual scores was defined as dermatitis score. (c) Behavior of AD-like mice was video recorded and the number of scratching behaviors was measured. Data are mean ± standard deviation (SD, n = 6). Days on x-axis are after sensitization. *P < 0.05, **P < 0.001, and ***P < 0.0001 versus DNCB treatment.

2.8. Measurement of Serum IgE Levels. The serum IgE levels were measured using mouse blood collected from the heart. The serum was analyzed using a Mouse IgE enzyme-linked immunosorbent assay (ELISA) MAX™ Deluxe (BioLegend, CA, USA) according to the manufacturer’s instructions by measuring the standard and sample absorbance values at 450 nm using a microplate reader.

2.9. RNA Preparation and Real-Time Polymerase Chain Reaction (qPCR). Total RNA was isolated from tissue extracted from the dorsal lesions using Tri-reagent (Sigma-Aldrich, St. Louis, MO, USA) according to the manufacturer’s instructions. The concentration of total RNA was determined using a spectrophotometer (GE Healthcare). Total RNA was used as a template for cDNA synthesis, which was performed using a cDNA Synthesis kit (Takara Bio, Shiga, Japan). The real-time polymerase chain reaction (qPCR) analysis was carried out using SYBR Green I and a Lightcycler® 96 instrument (Roche, Basel, Switzerland). The following primers were used: mouse IL-4, sense 5′-GGTCTCAACCCCCAGCTAGT-3′ and antisense 5′-GCCGATGATCTCTCTCAAGTGA-3′;
3. Results

3.1. Effect of CYM on IgE/DNP-BSA-Induced Passive Cutaneous Anaphylaxis. Passive cutaneous anaphylaxis was investigated to determine whether CYM affected local allergic responses in vivo. We locally sensitized the ears of mice by injecting them with IgE, followed by intravenous injection of DNP-BSA and Evans Blue solution. The CYM treatment group showed a suppressed local allergic response, which was similar to that observed after treatment with DPH, an antihistamine (Figures 1(a) and 1(b)).

3.2. Effect of CYM on DNCB-Induced Dermatitis in an AD-Like Mouse Model. Continuous DNCB treatment induced dermatitis in mice while CYM treatment reversed this AD-like effect (Figure 2(a)). To evaluate the condition of the mouse skin lesions, we measured skin severity scores for 11 days following sensitization. The continuous DNCB treatment not only aggravated the condition associated with the lesions on the dorsal skin, such as erythema, pruritus/dry skin, erosion, lichenification, and edema/excoriation but also increased the severity scores. However, CYM treatment improved the skin conditions 5 days following sensitization (Figure 2(b)). Scratching behavior was measured using 60 min video recordings of the mouse behaviors for 11 days following the sensitized AD-like skin severity test. During the behavioral observations, the blinded researcher counted the number of scratching behaviors, and, as shown in Figure 2(c), the group with continuous DNCB treatment exhibited an increase in the number of scratches to the dorsal skin.

2.10. Statistical Analysis. The experimental results are expressed as the mean ± standard deviation (SD). A one-way analysis of variance (ANOVA) was used for multiple comparisons followed by a Tukey-Kramer post hoc analysis. P values < 0.05, < 0.001, and < 0.0001 were considered statistically significant.

mouse IL-13, sense 5′-CCTGGCTCCTTGCTTGCTT-3′ and antisense 5′-GGTCTTGTGTAGTGTGCTCA-3′; mouse TNF-α, sense 5′-CTGTAAGCCACGTGATAGC-3′ and antisense 5′-TTGAGATCGCCGTTGGT-3′; and mouse β-actin sense 5′-ATGCCATCTCCTGGTCTGGACCTGGC-3′ and antisense 5′-AGCATTTGCAGTGGAGGG-3′. The denaturation, annealing, and extension conditions and number of cycles run were 94°C for 60 s, 49°C for 45 s, and 72°C for 45 s for 35 cycles, respectively.
However, treatment with CYM decreased scratching behavior 7 days following sensitization.

3.3. Effect of CYM on DNCB-Induced Histopathological Changes and IgE Level in an AD-Like Mouse Model. In AD, the thickness of skin lesions increases owing to the inflammatory condition, and serum IgE levels are upregulated. To measure skin thickness, enucleated skin lesion tissue was H&E-stained. Continuous DNCB treatment resulted in thickening of the epidermis and dermis of the dorsal skin compared with that of the nontreatment group. CYM treatment not only reduced the thickening of the dorsal skin but also resulted in a dorsal skin thickness that was similar to that of the nontreatment group (Figures 3(a) and 3(b)). The IgE serum levels were measured using a mouse IgE kit and the group that was continuously treated with DNCB exhibited an increased level. However, serum IgE levels of the CYM treatment group were effectively restored to levels that were similar to those of the nontreatment group (Figure 3(c)).

3.4. Effect of CYM on DNCB-Induced mRNA Expression of IL-4, IL-13, and TNF-α in AD-Like Mouse Model. Proinflammatory cytokines such as IL-4, IL-13, and TNF-α are known to induce inflammatory reactions. Therefore, the gene expression of these cytokines was analyzed using qPCR. As shown in Figure 4, the expression of mRNA increased in the DNCB treatment group while CYM efficiently suppressed this effect by 80%, 400%, and 90% for IL-4, IL-13, and TNF-α, respectively, compared with DNCB treatment.

3.5. Effect of CYM on Viability and IgE/DNP-BSA-Induced Degranulation of RBL-2H3 Cells. IgE/DNP-BSA-induced RBL-2H3 cell degranulation was measured using a β-hexosaminidase release assay. β-Hexosaminidase is
sensitized RBL-2H3 cells. IgE/DNP treatment induces degranulation in this study. IgE/DNP treatment activates a lysosomal enzyme and was used as a marker of RBL-2H3 cell degranulation. To sensitize RBL-2H3 cells, anti-DNP IgE (400 ng/mL) was added to culture medium. After 12 h, RBL-2H3 cells were washed with Siraganian buffer and treated with CYM (0, 25, 50, 100, or 200 μg/mL) in Siraganian buffer for 30 min. DNP-BSA (50 μg/mL) was added for 15 min. Cell supernatants were transferred to a 96-well plate, mixed with 1 mM p-NAG in 0.1 M citrate buffer for 1 h, and absorbance was measured at 405 nm using a microplate reader. Data are mean ± standard deviation (SD, n = 3). *P < 0.05 and **P < 0.001 versus nontreated RBL-2H3 cells.

3.6. Effect of CYM on IgE/DNP-BSA-Induced Phosphorylation of Syk, PLC-γ, Akt, Erk 1/2, JNK, and p38. The effect of CYM on IgE on specific signal transduction pathways was determined using western blot analysis. Signal transduction is usually initiated by extracellular signaling via receptors on the surface or inside the cell. IgE/DNP-BSA activates RBL-2H3 cells, thereby initiating signaling cascades. We investigated the phosphorylated signaling molecules related to RBL-2H3 cell degranulation. The phosphorylation of Syk is mediated by early FceRI signaling. The phosphorylation of Syk was decreased by CYM treatment by about 2-fold compared to that observed after IgE/DNP-BSA treatment. The PLC-γ-induced cleavage of phospholipids is related to calcium influx. The phosphorylation of PLC-γ was strongly decreased by about 3-fold by CYM treatment group compared to that observed after IgE/DNP-BSA treatment. CYM treatment also suppressed the phosphorylation of Akt by about 2.5-fold compared with IgE/DNP-BSA treatment. The Erk 1/2, JNK, and p38 proteins, which are subfamilies of MAPK, and their phosphorylation were suppressed by about 3-, 2.7-, and 2-fold, respectively, by CYM treatment (Figures 6(a) and 6(b)).

4. Discussion

The allergic response is related to mast cells, which are derived from myeloid stem cells. FceRI is located on the surface of mast cells and is a binding site for IgE [13–15]. In the presence of an allergen, the cross-linking of IgE and the allergen initiates mast cell activation [16]. Mast cells have a number of granules, and their activation induces not only degranulation but also the secretion of various factors such as histamine, leukotriene, prostaglandins, and other mediators from granules to various tissues and cells [20, 21]. They also express proinflammatory cytokines such as IL-4, IL-13, and TNF-α that induce inflammatory reactions [22, 23]. Here, IgE/DNP-BSA initiated the allergic response in vivo while CYM had an inhibitory effect on IgE/DNP-BSA-induced anaphylactic shock as shown by the PCA test (Figure 1).

Mast cells play critical roles in the allergic response and release a number of biologically active substances. To identify the therapeutic effects of CYM, we investigated the effect of DNCB induction in an AD-like mouse model [28, 29]. The continuous application of DNCB significantly increased the symptoms of dermatitis. However, CYM had therapeutic effects on DNCB-induced skin lesions in AD-like mice. In the severity test, the continuous application of DNCB aggravated the dorsal skin conditions such as erythema, pruritus/dry skin, erosion, lichenification, and edema/excoriation. As the inflammatory reaction worsened, the dorsal skin thickened. The application of DNCB not only increased the scratching behavior, which is a typical behavior in allergic dermatitis, but also abnormally upregulated the IgE levels in the serum of AD-like mice [30, 31]. CYM efficiently suppressed the increased skin severity, scratching behavior, epidermal thickness, and IgE levels (Figures 2 and 3). Additionally, CYM suppressed the gene expression of the proinflammatory cytokines IL-4, IL-13, and TNF-α (Figure 4) [23].

The initiation of an allergic response is followed by associated symptoms such as AD, anaphylactic shock, asthma, and conjunctivitis [4, 5]. CYM had an inhibitory effect on degranulation as shown in the β-hexosaminidase release assay (Figure 5). The degranulation of RBL-2H3 cells was controlled by cascades of multiple tyrosine kinases, and Syk is phosphorylated early in FceRI-mediated signaling. Syk phosphorylation activates signal transduction pathways such as the phosphoinositide 3-kinase (PI3K)/AKT and the MAPK pathways [1, 17]. Phosphorylation of PLC-γ, PIP2, DAG, and IP3 occurs following calcium ion influx into the cytosol through calcium channels [18]. An increased level of calcium ions in the cytoplasm also induces the degranulation of RBL-2H3 cells. The Akt and MAPK pathways regulate transcriptional activity. Consequently, phosphorylation of Akt, Erk 1/2, JNK, and p38 induces transcription of proinflammatory cytokine genes such as IL-4, IL-13, and TNF-α.
CYM was effective in inhibiting the degranulation of RBL-2H3 cells by suppressing the phosphorylation of various proteins such as Syk and PLC-γ and that of proinflammatory cytokines through the inhibition of phosphorylation of Akt, Erk1/2, JNK, and p38 (Figure 6). Therefore, CYM reduced AD by suppressing Syk-mediated degranulation of RBL-2H3 cells and gene expression of cytokines (Figure 7).

5. Conclusion

In conclusion, CYM had an antiallergic effect on dermatitis by inhibiting Syk-mediated signal transduction, suppressing proinflammatory cytokine gene expression and reducing serum IgE levels. We suggest that CYM may have therapeutic potential as an antiallergic agent for treating disorders such as AD.
Conflict of Interests
The authors declare that they have no conflict of interests regarding the publication of this paper.

Acknowledgments
The authors are grateful to Dr. Yusu Shin (National Institute Horticultural & Herbal Science, RDF, Korea) for providing them with the CYM. This research was supported by the Leading Foreign Research Institute Recruitment Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT & Future Planning (2010-00757).

References
[1] H. Motojima, M. O. Villareal, R. Iijima, J. Han, and H. Isoda, “Acteoside inhibits type I allergy through the down-regulation of Ca/NFAT and JNK MAPK signaling pathways in basophilic cells,” Journal of Natural Medicines, vol. 67, no. 4, pp. 790–798, 2013.
[2] H. S. Shin, M.-J. Bae, S. Y. Jung, and D.-H. Shon, “Preventive effects of skullcap (Scutellaria baicalensis) extract in a mouse model of food allergy,” Journal of Ethnopharmacology, vol. 153, no. 3, pp. 667–673, 2014.
[3] H. S. Park, Y. H. Hwang, M. K. Kim et al., “Functional polysaccharides from Grifola frondosa aqueous extract inhibit atopic dermatitis-like skin lesions in NC/Nga mice,” Bioscience, Biotechnology, and Biochemistry, vol. 79, no. 1, pp. 147–154, 2015.
[4] J. A. Garcia-Vilas, M. A. Medina, F. R. Melo, G. Pejler, and G. García-Faroldi, “Damnacanthal inhibits IgE receptor-mediated activation of mast cells,” Molecular Immunology, vol. 65, no. 1, pp. 86–93, 2015.
[5] H.-J. Chen, C.-K. Shih, H.-Y. Hsu, and W. Chiang, “Mast cell-dependent allergic responses are inhibited by ethanolic extract of Adlay (Coix lachryma-jobi L. var. ma-yuen Stapf) tests,” Journal of Agricultural and Food Chemistry, vol. 58, no. 4, pp. 2596–2601, 2010.
[6] T. Savinko, S. Matikainen, U. Saarialho-Kere et al., “IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors,” Journal of Investigative Dermatology, vol. 132, no. 5, pp. 1392–1400, 2012.
[7] O. B. Nilsson, J. Adedoyin, C. Rhyner et al., “In vitro evolution of allergy vaccine candidates, with maintained structure, but reduced B cell and T cell activation capacity,” PLoS ONE, vol. 6, no. 9, Article ID e24558, 2011.
[8] M. Niebuhr and T. Werfel, “Innate immunity, allergy and atopic dermatitis,” Current Opinion in Allergy and Clinical Immunology, vol. 10, no. 5, pp. 463–468, 2010.
[9] C. A. S. Parisi, P. L. Smaldini, M. E. Gervasoni, J. F. Maspéro, and G. H. Docena, “Hypersensitivity reactions to the Sabin vaccine in children with cow’s milk allergy,” Clinical and Experimental Allergy, vol. 43, no. 2, pp. 249–254, 2013.
[10] B. Yang, J. Li, X. Liu et al., “Herbal Formula-3 inhibits food allergy in rats by stabilizing mast cells through modulating calcium mobilization,” International Immunopharmacology, vol. 17, no. 3, pp. 576–584, 2013.
[11] D. Wang, M. Zheng, Y. Qiu et al., “Tespal negatively regulates FcεRI-mediated signaling and the mast cell-mediated allergic
Evidence-Based Complementary and Alternative Medicine

Marie Laurencin and their antioxidative activity,” Journal of Natural Medicines, vol. 67, no. 1, pp. 217–221, 2013.

[28] S.-J. Park, Y.-H. Lee, K. H. Lee, and T.-J. Kim, “Effect of eriodictyol on the development of atopic dermatitis-like lesions in ICR mice,” Biological and Pharmaceutical Bulletin, vol. 36, no. 8, pp. 1375–1379, 2013.

[29] J. H. Choi, S. W. Jin, B. H. Park et al., “Cultivated ginseng inhibits 2,4-dinitrochlorobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice and TNF-α/IFN-γ-induced TARC activation in HaCaT cells,” Food and Chemical Toxicology, vol. 56, pp. 195–203, 2013.

[30] S. Ständer and T. A. Luger, “Itch in atopic dermatitis—pathophysiology and treatment,” Acta Dermatovenerologica Croatica, vol. 18, no. 4, pp. 289–296, 2010.

[31] H. Metzger, “The receptor with high affinity for IgE,” Immunological Reviews, vol. 125, pp. 37–48, 1992.

response;” The Journal of Experimental Medicine, vol. 211, no. 13, pp. 2635–2649, 2014.

[12] S. Yamasaki and T. Saito, “Progress in allergy signal research on mast cells: signal regulation of multiple mast cell responses through FcεRI,” Journal of Pharmacological Sciences, vol. 106, no. 3, pp. 336–340, 2008.

[13] X.-Y. Yuan, H.-M. Ma, R.-Z. Li, R.-Y. Wang, W. Liu, and J.-Y. Guo, “Topical application of aloperine improves 2,4-dinitrofluorobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice,” European Journal of Pharmacology, vol. 658, no. 2-3, pp. 263–269, 2011.

[14] A. Hayashi, M. Kimura, Y. Nakamura, and H. Yasui, “Anti-atopic dermatitis effects and the mechanism of lactic acid bacteria isolated from Mongolian fermented milk,” Journal of Dairy Research, vol. 76, no. 2, pp. 158–164, 2009.

[15] E. H. Han, J. H. Park, J. Y. Kim, Y. C. Chung, and H. G. Jeong, “Inhibitory mechanism of saponins derived from roots of Platycodon grandiflorum on anaphylactic reaction and IgE-mediated allergic response in mast cells,” Food and Chemical Toxicology, vol. 47, no. 6, pp. 1069–1075, 2009.

[16] Y. Furumoto, G. Gomez, C. Gonzalez-Espinosa et al., “The role of Src family kinases in mast cell effector function,” Novartis Foundation Symposium, vol. 271, pp. 39–47, 2005.

[17] J. Kalesnikoff and S. J. Galli, “New developments in mast cell biology,” Nature Immunology, vol. 9, no. 11, pp. 1215–1223, 2008.

[18] M. V. M. Aadrade, T. Hiragun, and M. A. Beaven, “Dexamethasone suppresses antigen-induced activation of phosphatidylinositol 3-kinase and downstream responses in mast cells,” Journal of Immunology, vol. 172, no. 12, pp. 7254–7262, 2004.

[19] Y. Inoh, S. Tadokoro, H. Tanabe et al., “Inhibitory effects of a cationic liposome on allergic reaction mediated by mast cell activation,” Biochemical Pharmacology, vol. 86, no. 12, pp. 1731–1738, 2013.

[20] Z. Wu, X. Chen, F. Liu et al., “Calpain-1 contributes to IgE-mediated mast cell activation,” Journal of Immunology, vol. 192, no. 11, pp. 5130–5139, 2014.

[21] R. P. Siraganian, J. Zhang, K. Suzuki, and K. Sada, “Protein tyrosine kinase Syk in mast cell signaling,” Molecular Immunology, vol. 38, no. 16–18, pp. 1229–1233, 2002.

[22] E.-H. Sohn, S.-A. Jang, H. Joo et al., “Anti-allergic and anti-inflammatory effects of butanol extract from Arctium Lappa L,” Clinical and Molecular Allergy, vol. 9, article 4, 2011.

[23] M. M. Neis, B. Peters, A. Dreuw et al., “Enhanced expression level of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis,” Journal of Allergy and Clinical Immunology, vol. 118, no. 4, pp. 930–937, 2006.

[24] K. Yoshikawa, C. Baba, K. Iseki et al., “Phenanthrene and phenylpropanoid constituents from the roots of Cymbidium Great Flower ‘Marylaurencin’ and their antimicrobial activity,” Journal of Natural Medicines, vol. 68, no. 4, pp. 743–747, 2014.

[25] M. A. Howlader, M. Alam, K. T. Ahmed, F. Khatun, and A. S. Apu, “Antinociceptive and anti-inflammatory activity of the ethanolic extract of Cymbidium aloifolium (L.),” Pakistan Journal of Biological Sciences, vol. 14, no. 19, pp. 909–911, 2011.

[26] V. G. Gaytán, M. d. Mendoza, M. S. Hernández, L. I. Trejo-Téllez, M. E. Santos, and G. V. Ponce, “Volatile components in the flower, pedicellate ovary and aqueous residue of Cymbidium sp. (ORCHIDACEAE),” Journal of Analytical Sciences, Methods and Instrumentation, vol. 3, no. 4, pp. 212–218, 2013.

[27] K. Yoshikawa, M. Otsu, T. Ito, Y. Asakawa, S. Kawano, and T. Hashimoto, ‘Aromatic constituents of Cymbidium Great flower